EntityRisk’s Post

👏🏽 Amazing panel featuring Marcy Kravet of Inato, Jamila Watkins, MBA of Chinook Therapeutics, a Novartis Company, Patricia Cornet, MA and Melissa Cabral of Bristol Myers Squibb to educate us on including and applying insights from the patient voice in drug development before, during and after research. Here are some key takeaways from our dialogue at the #oectkpm summit: 🔍 For small biotechs, while resources are slim, coordinating a multifaceted approach can be easier 🌏 Diversity encompasses a spectrum far broader than race and ethnicity (yes, we still have to remind everyone!) 📚 Health literacy isn't merely about readability; it's about ensuring information is comprehensible and actionable for all 🏡 We must extend our considerations beyond clinical settings and factor in home life dynamics and their loved ones (pets included!) 💡 And let's not forget the treasure trove of patient insights waiting to be tapped into at research sites — truly invaluable for driving impactful outcomes #PatientVoice #DrugDevelopment #HealthcareInnovation #ClinicalResearch #ClinicalOperations #OECT

Exciting to share the below webinar #CRALifeSciences is hosting in a couple of weeks' time on the evolving business models in digital therapeutics. See the link to learn more and register! #DigitalTherapeutics

🌟  Transforming Health: One Byte at a Time! 🌟 At xBxBio, we're all about making a significant impact on health with cutting-edge science personalized just r you!  Imagine a world where treatments are tailored just like your favorite coffee! That's what xBxBio will do with diseases like cancer and Alzheimer's—making medicines that fit your unique genetic makeup perfectly. 💡 Why does this matter? Because personalized treatment means more effective care and, importantly, fewer side effects, reassuring you that treatments truly work for YOU! Our vision? A world where your medical treatment is as unique as you are, created faster, cheaper, and safer, thanks to our intelligent platforms that learn and adapt. 🚀 Join www.xbxbio.com on this incredible journey, where every discovery brings us closer to a healthier tomorrow. Learn more about how xBxBio is redefining medicine at www.xbxbio.com. #HealthTech #Innovation #PersonalizedMedicine #Biotechnology #DigitalHealth #PatientCare #SustainableHealthcare #DrugDevelopment #MedicalResearch #TechForGood #AIinHealthcare #MachineLearning #CloudComputing #DataScience #FutureOfHealthcare #EthicalTech #SmartHealthcare #HealthcareDisruption #VirtualHealth #Genomics #Bioinformatics #xTechForHealth #TransformHealthcare

Looking forward to joining fellow industry leaders at this year’s IDDST-International Drug Discovery Sciences & Technology Congress in Budapest! I am particularly excited to discuss how drug development in women’s health can uniquely leverage female biology to customize delivery methods and durations for optimized outcomes. If you are attending or will be in the area, let’s connect and talk all things #womenshealth!

Looking to share data from your publication, add a #visualabstract to help it jump out of the page, that's what Antonio Pisani and colleagues did for their new publication looking at patients moving from agalsidase beta to miglastat using the #fabry registry. Their findings indicate variability in long-term outcomes after switching from ERT to migalastat, underscoring the importance of careful monitoring. Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis Antonio Pisani, Kathryn Wilson, Julie Batista, Ilkka Kantola, Alberto Ortiz, Juan Manuel Politei, Laila Al-Shaar, Manish Maski, MD, MMSc, Ana Crespo, Elvira Ponce León, and Aleš Linhart https://lnkd.in/ePYRRuTz Sanofi Fabry International Network

As we look toward a promising 2024, the ADVI Health team is reflecting on some of the biggest issues, milestones, and regulations that helped to shape the #healthcare landscape in 2023. We asked #ADVIExperts to share the first key phrase or keyword that comes to mind regarding our critical work with clients. Which of the following responses resonate most with you and your organization? ▫️Innovation, specific to the development of new targeted therapies [and ADVI's unique opportunity to work at the intersection of molecular diagnostics and precision therapeutics] ▫️Real-time insights and evidence generation ▫️Software, specific to #healthpolicy developments for prescription digital therapeutics and artificial intelligence ▫️Empirically derived insights Hear from Lauren Feldman, Caitlin Sheetz, Michael Beebe, Peter Kardel, and more: https://lnkd.in/gF6H5b5p

Deal Cansino biologics partners with SPIMACO to bring menhycia vaccine for meningococcal disease to saudi arabia and key mena markets ➡ https://lnkd.in/gCWSX9PB Saniona and boehringer ingelheim amend ongoing collaboration, for CNS ion channel target drug candidates in schizophrenia treatment, with research funding ➡https://lnkd.in/g7pyNa6f Genequantum healthcare partners with biomap in strategic collaboration for development of novel ADC candidate, utilizing proprietary conjugation technology platforms ➡https://lnkd.in/gadXPbhQ Clinical Trials Sensorion's phase 2a trial of SENS-401 shows preliminary safety data in hearing disorders induced by cisplatin ➡ https://lnkd.in/ggJJJTaa Invivyd's phase 3 trial of INVYMAB shows high serum virus neutralizing antibody titer levels in immunocompromised participants for prevention of symptomatic COVID-19 ➡ https://lnkd.in/grFZ-XFV

Perfect timing for our webinar coming up next week April 24th. ⌚ Just days away from the news that Click Therapeutics and Otsuka secured FDA clearance for the first prescription digital program designed for adults with major depressive disorder (#MDD) Charles River Associates is holding a webinar on #digitaltherapeutics with the participation of Click Therapeutics, Inc. and DarioHealth Join to understand the challenges, the success factors and the latest trends on business models in #digitalhealth

Altura and its research partner Neighborhood Healthcare (FQHC) will present at the Festival of Biologics 2024 in San Diego on April 15 about the results of a grant-funded study related to building clinical trial and health research access and diversity via Community Health Centers. The study explored barriers preventing diverse populations from joining clinical studies and offers ways CHCs, life science companies and research organizations can help increase participation. If you would like a copy of the white paper, please email info@alturastudies.com. Thanks! #healthequity #clinicaltrials #healthaccess #chcs #lifescienceindustry

Metrodora Foundation is thrilled to announce the launch of MetX - a landmark study to deepen the biological understanding of chronic, complex conditions. The role of the Metrodora Foundation is to accelerate cures. We enlisted biopharma experts to explain why there weren’t more companies developing treatments for our patients, despite how large the need is. Their resounding response was that there isn’t enough quality patient data available to create a robust enough understanding of these diseases at the biological level. Therefore, it remains too risky for most pharma companies to prioritize these conditions. The most important information that biopharma asked us to compile is a 360 degree view of our patients - clinical information, like test results and electronic health information from patient visits, patient-reported information via surveys and wearables data, and in-depth biological information from genomics to immune profiling. No one else has collected such a comprehensive, longitudinal view of these patients. That is exactly what we’re launching today. And we’re doing so using patient-friendly technology that makes it easy for patients to share data, participate in research, and get value back in return. Read our announcement to learn more about how we're working with our partners to revolutionize collaborative research and improve patient outcomes. #LONGCOVID #MECFS #POTS #MIGRAINE #SJOGRENS #EDS #MCAS #CHRONICPAIN #FIBROMYALGIA #ENDOMETRIOSIS #FOODALLERGY #IBS #IBD #CHRONICILLNESS #INVISIBLEILLNESS https://lnkd.in/eZC2QGPq